Investor Presentation
- NCLT sanctioned demerger into 3 pure-play listed entities: Bio-Chemicals, Spirits & Biofuel, and Ennature Bio Pharma, removing conglomerate discount.
- Rapid growth in high-margin Ennature Bio Pharma segment with Q1 FY27 revenue up 65% and EBITDA up 188% YoY.
- Significant debt reduction driving Q1 FY27 finance costs down by 44% YoY (from ₹45 Cr to ₹25 Cr) with plan to become debt-free by FY28.
- Strong EBITDA guidance for Spirits segment (₹500 Cr target in FY27 and ₹1,000 Cr in 4-5 years) supported by price hikes in UP/Uttarakhand and new brand launches.
- This presentation reiterates details already disclosed in prior filings (Q1 results on Aug 12 and NCLT order on July 17), making the catalyst already priced in for the short term.
- High sensitivity to global petrochemical glycol prices; lower petro-glycol prices depress bio-glycol spreads and BSPC segment margins.
- State government regulation on potable alcohol pricing and inter-state movement controls in key markets (UP and Uttarakhand).
- Net debt remains substantial at ₹1,691 Cr (D/E 0.67), making debt reduction timelines critical.
India Glycols Limited (INDIAGLYCO) — Equity Research Report
Analysis Date: 2026-08-14
Price: ₹1,047.60 | Market Cap: ₹6,651 Cr | TTM P/E: 22.7x
1. Executive Summary & Restructuring Catalyst
India Glycols' Investor Presentation on August 14, 2026, outlines a transformative corporate restructuring and financial deleveraging roadmap following the NCLT approval (sanctioned July 17, 2026) to demerge into three pure-play listed platforms: 1. Bio-based Chemicals: Core green glycols and JV with Clariant. 2. Spirits & Bio-Fuel (IGL Spirits): Ethanol blending supply to OMCs, Country Liquor, and expanding premium IMFL portfolio. 3. Ennature Bio Pharma: Fast-growing nutraceuticals and active botanical extracts.
While the demerger approval itself was disclosed on July 17/20, 2026 and Q1 FY27 earnings were reported on August 12, 2026 (making near-term fundamental news already priced in), the granular segment targets present a clear long-term value-creation thesis. Management targets ₹500 Cr EBITDA in Spirits for FY27 (scaling to ₹1,000 Cr over 4–5 years) and a debt-free operational profile by FY28.
2. Ramp-Aware Financial & Valuation Impact Math
- Current TTM Financials:
- Revenue: ₹8,443 Cr | Operating Profit: ₹616 Cr (OPM: 7.3%) | PAT: ₹293 Cr | EPS: ₹46.09
-
Debt: ₹1,691 Cr | Net Worth: ₹2,538 Cr | D/E: 0.67x | ROCE: 13.0%
-
Deleveraging Momentum:
- Q1 FY27 finance costs declined 44% YoY to ₹25 Cr (vs. ₹45 Cr in Q1 FY26), directly boosting bottom-line expansion (Q1 PAT up 32.2% YoY to ₹96.8 Cr).
-
Annualized interest savings of ~₹80 Cr convert directly to pre-tax earnings.
-
Segment Growth Drivers:
- Ennature Bio Pharma: Best-ever Q1 with 65% revenue growth and 188% EBITDA expansion. As a standalone listed entity, this high-margin unit will command premium valuation multiples (25–30x P/E vs IGL's unified 22.7x).
-
Spirits Segment: Price hikes in UP/Uttarakhand and launch of proprietary brands (Zumba Lemoni, Soulmate Blu) drive OPM expansion toward the ₹500 Cr FY27 EBITDA target.
-
Earnings Trajectory & EPS Uplift:
- FY27 Estimated PAT: ~₹380–400 Cr (driven by interest savings + 12% revenue growth + margin expansion in Spirits/Pharma).
- Estimated FY27 EPS: ~₹61.0–64.5 (vs TTM ₹46.09, representing ~35–40% EPS expansion).
3. Industry Context & Quality Gate
- Capital Intensity & Execution: Medium capital intensity. Distillery expansion requires ~₹365 Cr over 2 years, funded partially via internal accruals.
- Industry CAGR: Expected structural CAGR of 11.5% across biofuel ethanol mandates, IMFL premiumization, and global green chemistry adoption.
- Quality Gate Assessment: Passes. Trailing ROCE of 13.0% is moderate due to legacy commodity glycol drag, but structural shift toward high-margin Spirits and Bio Pharma will elevate return ratios post-demerger.
4. Scenario Analysis & Valuation
| Scenario | Assumptions | Target Market Cap (₹ Cr) | Target Price (₹) | Upside/Downside |
|---|---|---|---|---|
| Bull Case | Demerger unlocks sum-of-the-parts value; Spirits EBITDA reaches ₹1,000 Cr in 4 yrs; Biopharma commands 30x P/E; Debt-free by FY28. | ₹14,630 Cr | ₹2,300 | +120.0% |
| Base Case | FY27 PAT reaches ₹390 Cr; SOTP multiple of 18x average across 3 demerged units; debt declines per plan. | ₹10,310 Cr | ₹1,620 | +55.0% |
| Bear Case | Petrochemical glycol prices collapse, hurting Bio-Chemical margins; state regulatory hurdles hit Spirits pricing. | ₹4,990 Cr | ₹785 | -25.0% |
5. Verdict Rationale
- Verdict: POSSIBLE (Multibagger Score: 70/100)
- Rationale: The demerger is a major structural catalyst that will eliminate the conglomerate discount and allow high-margin segments (Ennature Bio Pharma and IGL Spirits) to re-rate to industry-standard peer multiples. Combined with strong debt reduction and margin expansion, the company has strong multi-year compounding potential. The score is capped at 70 because near-term news is already priced in post-NCLT sanction and ROCE currently sits at a moderate 13.0%.
